Kota Kendari

Researchers are evaluating how probiotics containing Lactobacillus species affect vaginal bacteria and immune responses in postmenopausal women with bacterial vaginosis. The study recognizes that hormonal changes after menopause reduce Lactobacillus, which normally protects against harmful bacteria, increasing the risk of bacterial vaginosis. This trial investigates whether probiotic treatment can help restore a healthy vaginal environment and balance immune function in this group. All participants diagnosed with bacterial vaginosis will first receive a standard antibiotic treatment with metronidazole, either orally or intravaginally, for five days. After a 48-hour break, they will be randomly assigned to one of two groups: one receiving Floragyn4 probiotic tablets daily for two weeks, and the other receiving a daily placebo tablet called Cal954. A control group of healthy postmenopausal women without bacterial vaginosis will also take Floragyn4 for two weeks to compare effects. Participants will provide vaginal swabs and blood samples before treatment, after antibiotic therapy, and four weeks following the probiotic or placebo course. Researchers will measure vaginal pH, glucose, protein, and bacterial composition, as well as blood markers of inflammation and immune function. These assessments aim to understand changes in vaginal bacteria and immune markers over time. The total study duration includes antibiotic treatment, probiotic or placebo administration, and follow-up sampling at one and seven weeks.